INDV — Indivior Pharmaceuticals Inc
$35.25+1.38%
Last close: · regular session
Last 60 sessions
INDV closed at $35.25 (+1.38%) on Oct 29, 2026. Recent offering filing (424B3, Sep 2026). Float: 116.6M shares. Latest SEC filing: 425 on Oct 29, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for INDV in the TickerWise workspace.
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NASDAQ
- Employees: 1,030
- Website: https://www.indivior.com
Latest SEC filings for INDV
Latest INDV news
- Indivior Non-GAAP EPS of $1.32 beats by $0.19, revenue of $356M beats by $26.65M Read article
- Indivior Q3 2026 Earnings Preview Read article
- Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders Read article
- Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound? Read article
- Indivior to Report Second Quarter 2026 Financial Results and Host Webcast Read article
- What to Know About This Fund's $74.8 Million Indivior Sale Read article
- Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder Read article
- Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.